Welcome to the Investor Relations section of the Ergomed website.


This area is dedicated to keeping shareholders and potential investors up to date with share price, news and other relevant information. It includes information we are required to share on our website by the AIM Rules for Companies.

Last Update

10 August 2018

Stock Code

ERGO

No of Shares in Issue

44, 858, 94.

No of Treasury Shares

0

Accounting Year End

31 December

Country of Incorporation

England

Main Country of Operation

United Kingdom

Date Listed

24 July 2014

Index Market

AIM

ERGOMED
Surrey Research Park
1 Occam Court
Guildford Surrey GU2 7HJ
United Kingdom

The following information is disclosed in accordance with Rule 26 of the AIM Rules for Companies.

Company Information

Founded in 1997, Ergomed plc is a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. It operates globally in over 55 countries.

  1. Ergomed plc has two complementary businesses:
    The Services Business – a well-established, clinical research business providing services to the pharmaceutical and biotechnology industry
  2. The Co-Development Business – a growing portfolio of partnerships with pharmaceutical and biotech companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including outlicensing milestones as well as sales of the product

Since its formation, Ergomed plc has been providing expertise in clinical development / trial management from the largest pharmaceutical companies, as well as many small and mid-sized drug development companies. Ergomed plc successfully manages clinical development from Phase I through to late phase programmes.

Ergomed plc has a wide therapeutic focus, but has particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed plc believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed plc and the investigational sites involved in clinical trials. As well as providing high quality clinical development services, Ergomed plc is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed plc leverages its expertise and services in return for carried interest in the drugs under development.

The company has planned, managed, monitored, and reported clinical trials with a range of technologies that include small molecule drugs, monoclonal antibodies, tri-functional antibodies, soluble receptors and other targeted agents, cancer vaccines and immunotherapy, radioactive agents, and photodynamic therapies.

ERGOMED PLC
1 Occam Court
Surrey Research Park
Guildford Surrey GU2 7HJ
United Kingdom

Corporate Governance

The Directors of the Company are responsible for preparing the financial information in accordance with International Financial Reporting Standards as adopted by the European Union. It is our responsibility to form an opinion on the financial information and to report our opinion to you.

Save for any responsibility arising under paragraph (a) of Schedule Two to the AIM Rules for Companies to any person as and to the extent there provided, to the fullest extent permitted by law we do not assume any responsibility and will not accept any liability to any other person for any loss suffered by any such other person as a result of, arising out of, or in connection with this report or our statement, required by and given solely for the purposes of complying with Annex I item 23.1 of the Prospectus Directive Regulation as applied by Paragraph (a) of Schedule Two to the AIM Rules for Companies, consenting to its inclusion in the Admission Document.

The board recognises the importance of sound corporate governance and has adopted the QCA Corporate Governance Code (published in April 2018 by the QCA Code Companies Alliance (“QCA”). The QCA Code state that “Companies need to deliver growth in long term shareholder value. This requires an efficient, effective and dynamic management framework and should be accompanied by good communication which helps to promote confidence and trust.”

Ergomed’s Chairman has made a Corporate Governance Statement in accordance with the QCA Code , explaining how Ergomed complies with the ten principles of the QCA Code. The Corporate Governance Statement will be updated annually.

Board Committees

The Audit and Risk Committee has Christopher Collins as Chairman, and has primary responsibility for monitoring the quality of internal controls, ensuring that the financial performance of the Company is properly measured and reported on and reviewing reports from the Company’s auditors relating to the Company’s accounting and internal controls, in all cases having due regard to the interests of Shareholders.

The Audit and Risk Committee  meets at least twice a year. Peter George is the other member of the Audit and Risk Committee.

The Remuneration Committee has Christopher Collins as Chairman, and reviews the performance of the executive directors and determines their terms and conditions of service, including their remuneration and the grant of options, having due regard to the interests of Shareholders.

The Remuneration Committee meets at least twice a year. Peter George and Stephen Stamp are the other members of the Remuneration Committee.

The Nomination Committee has Peter George as Chairman, and identifies and nominates for the approval of the Board, candidates to fill board vacancies as and when they arise.

The Nomination Committee meets at least twice a year. Dr. Miroslav Reljanovic and Christopher Collins are the other members of the Nomination Committee.

The AIM Compliance and Corporate Governance Committee has Christopher Collins as Chairman and has been established to ensure that the Company is complying with the AIM Rules. In addition the Commitee assesses the Company’s corporate governance obligations. Peter George is the other member of the AIM Compliance and Corporate Governance Committee.

Number of Ordinary Shares in issue: 44,888,947

Number of Ordinary Shares in issue held as treasury stores: 0

Shareholder Analysis as of 10 August 2018

Shares not in public hands (owned by Directors) 28.00%

Significant Shareholders

Dr. Miroslav Reljanovic 24.82%

Slater Investments Ltd 9.96%

Octopus Investments 6.80%

Strategic Equity 5.24%

BlackRock 5.04%

Livingbridge 4.67%

Fullbrook Thorpe Investments 3.75%

Rathbones 3.52%

Harwood Capital 3.25%

Business Growth Fund 3.18%

Miton Asset Management 3.10%

 

TR-1 Forms should be sent to ir@ergomedplc.com

In addition to the AIM market, the Company’s shares are also traded on Xetra, the electronic trading system of Deutsche Börse AG in Germany. The ISIN is GB00BN7ZCY67 and the ticker symbol is ZEMGR.

The Company is subject to the UK City Code on Takeovers and Mergers

This information is being provided for AIM Rule 26 compliance

This page was last updated September 2018.

Nominated Adviser & Joint Broker

Numis Securities Limited
10 Paternoster Square
London
EC4M 7LT

Financial PR (UK)

Consilium Strategic Communications
41 Lothbury
London
EC2R 7HG

Registrars

Share Registrars Limited
The Courtyard, 17 West Street
Farnham, Surrey
GU9 7DR

Solicitors to the Company

Covington & Burling LLP
265 Strand
London
WC2R 1BH

Financial PR (Continental Europe)

MC Services AG
Kaiser Friedrich Ring 5
40545 Dusseldorf
Germany

The below analysts follow Ergomed. To obtain a copy of their research reports, please contact their respective institutions.

Numis Securities Limited

Stefan Hamill

Equity Development

Elizabeth Klein

Access Equity Development’s reports here.

GBC AG

Felix Gode

Access GBC AG’s research reports here.

Millions of people fall victim to scams every year, from experienced investors to people dealing with a large sum for the first time. They may offer to sell shares that turn out to be worthless or non-existent, or to buy shares at an inflated price in return for an upfront payment. While high profits are promised, if you buy or sell shares in this way you will probably lose your money.

‎In particular, it has come to our attention that individuals have been sent letters purporting to come from Ergomed together with a contract note asking for payment to be made to an account in settlement of a share purchase. These are not from the Company and the adviser referred to in these letters, Applied Finance Group, have not been engaged by the Company for any purposes and you should not transfer any money to them.

Protect yourself

Investment scams are designed to look like genuine investments. You should take these steps to spot and avoid them before handing over any money:

  1. You should treat the call with extreme caution. Get the name of the person and the organisation contacting you.
  2. Check the FCA Warning List to ensure they are authorised.
  3. Use the details on the Financial Services Register to contact the firm.
  4. Call the FCA Consumer Helpline on 0800 111 6768 if there are no contact details on the Register or you are told they are out of date.
  5. Search the list of unauthorised firms and individuals to avoid doing business with at www.fca.org.uk scams

Report a scam

If you think you have been contacted by share you should tell the FCA using the share fraud reporting form or call the FCA Consumer Helpline on 0800 111 6768.‎

If you have lost money to investment fraud, you should report it to Action Fraud on 0300 123 2040 or online at www.actionfraud.police.uk

Board of Directors

Peter George

Chairman

Peter George

Chairman

Peter George joined Ergomed as a non-executive director in May 2014 and has over 20 years’ experience in the pharmaceutical services industry. Peter stepped down as Chief Executive Officer of Clinigen Group plc (AIM: CLIN) at the end of 2016. He started Clinigen in 2010 as a global specialty pharmaceuticals and pharmaceutical services business and by 2016 it had a c.£1bn market cap, being one of the most successful recent floats on AIM.

Prior to Clinigen, he was CEO at Penn Pharma, having led a £67m management buy-out in 2007. Before this, Peter was executive Vice President for Wolters Kluwer Health with responsibility for Europe and Asia Pacific regions.

Peter has also held roles as the Chief Operating Officer of Unilabs Clinical Trials International Limited, and Head of Clinical Pathology NHS.

Peter is also Chairman of Wichtig International, Mitre Group Limited, XPG Ltd, Marco Polo Events Limited, and Benchmark Holdings PLC, companies he owns or has significant holdings in.

Peter is the Chair of Ergomed’s Nomination Committee and is a member of the Audit and Risk, AIM Compliance and Remuneration Committees.

Dr Miroslav Reljanović

Founder and Executive Vice-Chairman

Dr Miroslav Reljanović

Founder and Executive Vice-Chairman

Dr Miroslav Reljanovic is a medical doctor and a board-certified neurologist. Whilst practicing as a physician in a large WHO Collaborating Centre in Zagreb, he was the clinical investigator in numerous Phase II and III studies in the field of neurology and a consultant to various pharmaceutical companies. In 1997 Miro founded Ergomed and he introduced the novel Study Site Coordination model as an intrinsic part of the conduct of clinical studies. This model became a landmark of the Ergomed approach to clinical research, which is paramount to provide high quality.

Miro successfully introduced the first European innovative co-development business model and he has completed several partnerships with European and North American listed biopharmaceutical companies. Together with co-founder Elliot Brown, MB, MRCGP, FFPM, a well-known international expert in drug safety, Miro started PrimeVigilance in 2008, which soon became a leading specialist vendor of contracted pharmacovigilance services to the pharmaceutical industry.

Miro led Ergomed through a successful IPO on the AIM market of the London Stock Exchange in July 2014 and the subsequent completion of five acquisitions and a secondary offering.

Miro transitioned to Executive Vice-Chairman in July 2017 in order to support the Board in growing and developing Ergomed’s CRO offering and to provide strategic guidance on Ergomed’s co-development business and wholly-owned pipeline.

Miro is a member of Ergomed’s Nomination Committee.

Stephen Stamp

Chief Executive Officer

Stephen Stamp

Chief Executive Officer

Stephen Stamp joined Ergomed in January 2016 as Chief Financial Officer and in December 2017 he was appointed Chief Executive Officer. Stephen brings to Ergomed more than 30 years of experience in corporate finance and general management in both public and private companies in the UK and the USA. Stephen joined Ergomed from US-based AssureRx Health, Inc, a personalised medicine and bio-informatics company, where he was CFO. Prior to this he was CFO of EZCORP, Inc. (NASDAQ:EZPW), a consumer financial services company and Chief Operating Officer and CFO at Xanodyne Pharmaceuticals, Inc, a specialty pharmaceutical company.

Before leaving for the US, Stephen was Group Finance Director at Shire Pharmaceuticals (LSE:SHP, NASDAQ:SHPG) where he led the IPO on the London Stock Exchange as well as a number of major acquisitions and financings. During his time at the Company, Shire’s market capitalisation increased from GBP20 million to GBP3.1 billion. He was also Group Finance Director at Regus Plc (LSE:RGU) where he successfully listed the Company on London Stock Exchange Main Market and NASDAQ. Earlier in his career, Stephen was an investment banker with Lazard in London, advising mainly public companies on cross-border M&A and corporate finance. Prior to Lazard, he worked for KPMG in London where he qualified as a Chartered Accountant.

Stephen is a member of Ergomed’s Remuneration Committee.

Stuart Jackson

Chief Financial Officer

Stuart Jackson

Chief Financial Officer

Bringing over 20 years’ experience at the Chief Financial Officer level, Stuart has managed companies on the London, NASDAQ and Oslo Stock Exchanges. He has significant international experience in early stage and growth companies as well as managing significant and complex change projects. Stuart’s experience has been gained primarily in the energy and technology/telecommunications sectors where consistent project service delivery across a number of geographies has been a key feature of business success.

To expand on some of Stuart’s achievements; he was CFO at Acergy SA responsible for the financial restructuring of the business and implementation of the new business strategy which took Acergy from $0.1bn to $6.0bn market capitalisation over a four year period. Recently he was CFO at CEONA, where he was responsible for the early stage set-up and growth of the business. He was also CFO at Bibby Offshore Holdings Limited where he also managed the strategic development and M&A activities and oversaw its recent recapitalisation.

Dr Jan Petracek

Chief Operating Officer

Dr Jan Petracek

Chief Operating Officer

Dr Jan Petracek is an internationally recognised entrepreneur and expert in pharmacovigilance, leading critical developments in the field and implementing the latest technology and science. He has proven his entrepreneurship skills by establishing multiple successful organisations in non-profit (medical student union – TRIMED), government (new pharmacovigilance and risk management departments of national (SUKL) and European (EMA) regulators), as well as private profitable businesses (PharmInvent).

Jan is a medical doctor (Charles University in Prague) and holds an MSc with distinction (Imperial College London) in Quality and Safety in Healthcare. He is on the Board of the International Society of Pharmacovigilance, leading development of the Global Standard for Career Framework in Pharmacovigilance. He is a popular international speaker at pharmacovigilance conferences and training seminars.

While being the Head of Risk Management at the European Medicines Agency (until 2010), Jan was leading development of the guidelines for risk management of Advanced Therapies, ICH guidelines, and contributed to the foundation of EU Good Pharmacovigilance Practice. In his consulting career (since 2010), he has worked as an EU QPPV, auditor, system architect, and strategic advisor for global, mostly US based companies.

Jan joined Ergomed in November 2016 and serves as CEO of PrimeVigilance and PharmInvent. In December 2017 he was appointed Chief Operating Officer of Ergomed Plc.

Andrew Mackie

Chief Business Officer

Andrew Mackie

Chief Business Officer

Andrew Mackie joined Ergomed as Chief Business Officer in 2015 having worked with the company as a consultant since 2004. He has been instrumental in developing the co-development business and negotiating the partnerships signed to date. Andrew joins from the Business Development group at Eli Lilly. Previously he was Head of Life Sciences at IP Group and Head of Alliance Management at Antisoma. He brings with him over 25 years’ industry experience in pre-clinical research, clinical development and business development.

After ten years in R&D positions at Novartis, Sanofi and MDS, Andrew joined the UK biotech sector in 1996 at Antisoma as Head of Clinical Development. He established the clinical development department which ran several oncology Phase I to Phase III programmes and later managed their strategic alliance with F Hoffman-La Roche. The role also included in-licensing new drug leads. At IP Group, he managed several portfolio companies and worked with the University partners to create new businesses.

Andrew holds a BSc in biochemistry from Queen’s University (Canada), an LLB from the University of London and an MBA from the London Business School.

Christopher Collins

Non-Executive Director

Christopher Collins

Non-Executive Director

Christopher was the CEO and a founding partner of Code Securities, a healthcare focused advisory and broking firm, which was formed in 2003, acquired by Nomura in 2005 and continued as Nomura Code Securities until late 2013.

Chris was previously head of the Life Sciences Group at WestLBPanmure, having founded that firm’s activities in the sector in 1993. He has advised companies at all stages of development on transactions including private financings, IPOs, secondary offerings and mergers and acquisitions.

Prior to WestLBPanmure, Chris was Managing Director of Corporate Finance at Panmure Gordon, after eight years as a Director of Corporate Finance at Hoare Govett and nine years in Corporate Finance at Charterhouse Japhet. He has an MBA and read biology at Sussex University.

Chris is the Chair of Ergomed’s Audit and Risk, AIM Compliance and Remuneration Committees and is a member of the Nomination Committee.

Sanja Juric

General Counsel and Company Secretary

Sanja Juric

General Counsel and Company Secretary

Sanja Juric joined Ergomed in 2016 after more than 30 years’ career in international law and after having assisted Ergomed as its outside advisor for more than 15 years. As Ergomed’s counsel, Sanja has been on Ergomed core co-development team since the first deal and helped close several co-development transactions.

Sanja holds degrees from the University of Zagreb (LLB, 1985) and the University of Fordham, School of Law, New York City (LLM in International Trade and Business Law, 1992). She has been admitted to the Bar of the State of New York since May 1993 and is listed as an arbitrator with the Chamber of Commerce in Croatia.

Sanja’s experience encompasses both in-house positions, including that of the head of legal affairs of the largest Croatian private company, during the period of its intense expansion via acquisitions and law firm positions. Prior to joining Ergomed, Sanja provided consulting to international businesses and organizations (including IFC, DEG, Avon, Kleeman, Herbalife) and cooperated with multinational law firms (Baker & McKenzie) focusing on cross-border transactions, primarily M&A. Sanja wrote extensively for several international M&A handbooks and participated for many years as an author in the World Bank series of “Doing Business”.